OncoMethylome shareholders pass all resolutions at AGM and appoint three new independent directors
(Thomson Reuters ONE) -
DURHAM, NC, and LIEGE, BELGIUM - May 31, 2010, 8:00 CET - OncoMethylome Sciences
SA (Euronext Brussels: ONCOB, Euronext Amsterdam: ONCOA), a leading molecular
diagnostics company, today announced that its Annual General Shareholders'
Meeting (AGM) held on 28 May, 2010, approved the appointment of Ms. Hilde
Windels, Mr. Edward L. Erickson, and Mr. Mark Myslinski to the Board of
Directors, as well as all other agenda items of the AGM. The appointment of the
new directors is effective immediately for a period until the 2013 AGM.
Dr. Jan Groen, Chief Executive Officer of OncoMethylome, said: "I am delighted
that our shareholders have appointed these directors who bring a wealth of
relevant experience, and vision to OncoMethylome. Our management and board look
forward to working together and benefit from their strong record of achievements
in finance, life sciences and the commercial lab service industry that will
prove extremely valuable to OncoMethylome's further growth."
Ms. Hilde Windels (1965), a Belgian national, is currently CFO of two
biotechnology companies, Pronota NV and SEPS Pharma NV. For nearly 10 years she
was CFO of Devgen NV, a publicly listed Belgian biotech company, where she led
the company's IPO on Euronext Brussels, managed investor relations, and also
acted as Head of the pharma business unit during 2008. Prior to working in the
biotech sector, she was employed for over 10 years at ING Bank. Mrs. Windels
will also serve on OncoMethylome's Audit Committee. Ms. Windels holds a Master's
degree in applied economics from Leuven University.
Mr. Edward L. Erickson (1946), an American national, has served as President,
CEO, and Director of over a dozen life sciences companies. During his tenure at
these firms he played a central role in numerous financial and business
transactions, overseeing product development programs and launches, and shaping
strategies for growth. Over the last 20 years, Mr. Erickson was president and
CEO of three formerly NASDAQ-listed biotech companies (Immunicon Corporation,
DepoTech Corporation, and Cholestech Corporation). He is currently the interim
CEO of BioNanomatrix Inc., board member of Metabolon Inc., Molecular Biometrics
Inc., and Zetek LLC. Mr. Erickson holds an MBA from Harvard University.
Mr. Mark Myslinski (1955), an American national, is President and CEO of RedPath
Integrated Pathology Inc., a US-based CLIA diagnostics laboratory that will be
acquired by the French company ExonHit Therapeutics. Mr. Myslinski will be the
CEO of Redpath and the president of the global diagnostics business unit of
ExonHit. Additionally, he serves on the Management Committee of ExonHit. Mr.
Myslinski has over 30 years of experience in the healthcare industry, with a
focus on diagnostics, and has held management positions at Johnson & Johnson,
Baxter, American Hospital Supply Corporation and various venture-backed
start-ups. Mr. Myslinski holds an MBA from Ohio University.
Dr. Robert Timmins (age 77) and Mr. Gerard Vaillant (age 69) have retired from
the Board effective May 28, 2010. "We are grateful to Dr. Timmins for his
leadership, diligence, and hard work, provided to the company over the last
seven as Chairman of the Board. We also thank Mr. Vaillant for his contribution
to the Board over the last year", added Dr. Jan Groen.
About OncoMethylome Sciences
OncoMethylome Sciences is a leading molecular diagnostics company that
commercializes and develops cancer-screening tests to assist physicians in
detecting and treating cancer early. The company's tests are based on
proprietary gene methylation technology invented at Johns Hopkins University and
are designed to help the physician accurately detect early stages of cancer
development, predict a patient's response to drug therapy, and predict the
likelihood of cancer recurrence. OncoMethylome Sciences collaborates with
leading cancer research centers, such as Johns Hopkins, in Baltimore, MD, and
has a number of commercial and collaborative partnerships with LabCorp,
Schering-Plough, GlaxoSmithKline Biologicals, Millipore Corporation's BioScience
Division, Roche, Merck KGaA and Qiagen.
For more information:
Dr. Jan Groen
CEO
+32 4.364.20.70 office
IR(at)oncomethylome.com
This press release contains forward-looking statements and estimates with
respect to the anticipated future performance of OncoMethylome and the market in
which it operates. Such statements and estimates are based on assumptions and
assessments of known and unknown risks, uncertainties and other factors, which
were deemed reasonable but may not prove to be correct. Actual events are
difficult to predict, may depend upon factors that are beyond the Company's
control, and may turn out to be materially different.
[HUG#1420022]
2010-5-31 New BOD Members ENG: http://hugin.info/137314/R/1420022/369779.pdf
Unternehmensinformation / Kurzprofil:
Datum: 31.05.2010 - 08:01 Uhr
Sprache: Deutsch
News-ID 21682
Anzahl Zeichen: 0
contact information:
Town:
Liège
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 239 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OncoMethylome shareholders pass all resolutions at AGM and appoint three new independent directors"
steht unter der journalistisch-redaktionellen Verantwortung von
OncoMethylome Sciences (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
